Latest Vascepa Lawsuit Plunges Hikma Into Induced Infringement Battle
Amarin Files Over Icosapent Ethyl Capsules And Cardiovascular Indication Patents
Executive Summary
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
You may also be interested in...
Industry Impact Weighed As US Supreme Court Refuses Skinny-Label Review
Teva has been denied in its attempt to convince the US Supreme Court to re-examine long-running litigation with GSK over skinny-label carve-outs of generic indications. However, the generics firm has vowed to fight on as the case is returned to the district court level, while the wider off-patent industry weighs the impact of the latest decision.
Vascepa Infringement Dismissal ‘Resulted In Multiple Errors,’ Amarin Argues
Amarin is digging deep to take Hikma back before a US district court in its induced infringement case against the generics manufacturer.
Hikma Triumphs As Vascepa Induced-Infringement Case Dismissed
An attack on Hikma’s skinny-label generic version of Vascepa by originator Amarin, claiming induced infringement of patents protecting a cardiovascular indication, has been dismissed in the US.